bioAffinity Technologies, Inc. (BIAFW) — This stock currently has no analyst coverage. No price targets, ratings, or earnings estimates are available. This is common for preferred shares, warrants, OTC-traded securities, and smaller companies that are not followed by Wall Street analysts.
Analysten schätzen Gewinn pro Aktie (EPS) von $-20.70 und Umsatz von $0.01B für das nächste Geschäftsjahr.
Gewinn pro Aktie (EPS) Erfolgsbilanz: 2024: tatsächlich $-0.73 vs Schätzung $-20.70 (übertroffen +96.5%). 2025: tatsächlich $-8.66 vs Schätzung $-14.40 (übertroffen +39.9%). Analysten-Genauigkeit: 0%.
GpA-Schätzungen — BIAFW
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.73
vs Est –$20.70
▲ 2,735.6% off
2025
Actual –$8.66
vs Est –$14.40
▲ 66.3% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Umsatzschätzungen — BIAFW
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.009B
vs Est $0.010B
▼ 2.2% off
2025
Actual $0.006B
vs Est $0.006B
▲ 1.2% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
